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Background: Polycystic Kidney Disease (PKD) kidneys exhibit increased extracellular matrix (ECM) collagen
expression and metalloproteinases (MMPs) activity. We investigated the role of these increases on cystic disease
progression in PKD kidneys.
Methods: We examined the role of type I collagen (collagen I) and membrane bound type 1 MMP (MT1-MMP) on
cyst development using both in vitro 3 dimensional (3D) collagen gel culture and in vivo PCK rat model of PKD.
Results: We found that collagen concentration is critical in controlling the morphogenesis of MDCK cells cultured
in 3D gels. MDCK cells did not form 3D structures at collagen I concentrations lower than 1 mg/ml but began
forming tubules when the concentration reaches 1 mg/ml. Significantly, these cells began to form cyst when
collagen I concentration reached to 1.2 mg/ml, and the ratios of cyst to tubule structures increased as the collagen
I concentration increased. These cells exclusively formed cyst structures at a collagen I concentration of 1.8 mg/ml
or higher. Overexpression of MT1-MMP in MDCK cells significantly induced cyst growth in 3D collagen gel culture.
Conversely, inhibition of MMPs activity with doxycycline, a FDA approved pan-MMPs inhibitor, dramatically slowed
cyst growth. More importantly, the treatment of PCK rats with doxycycline significantly decreased renal tubule
cell proliferation and markedly inhibited the cystic disease progression.
Conclusions: Our data suggest that increased collagen expression and MMP activity in PKD kidneys may induce
cyst formation and expansion. Our findings also suggest that MMPs may serve as a therapeutic target for the
treatment of human PKD.
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Polycystic kidney diseaseBackground
Polycystic kidney disease (PKD) is the most common
genetic disorder of the kidneys and is characterized by
the progressive formation and enlargement of fluid-filled
cysts. These cysts compress the normal adjacent paren-
chyma, ultimately leading to end-stage renal disease that
requires dialysis and renal transplantation [1,2]. The
two major inherited forms of PKD are Autosomal
Dominant PKD (ADPKD) and Autosomal Recessive* Correspondence: yunxia.tao@ttuhsc.edu
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reproduction in any medium, provided the orPKD (ARPKD). ADPKD is caused by a mutation in
either the PKD1 or PKD2 genes and is manifested in
adulthood with an incidence of 1:1000. ARPKD is
caused by mutation in PKHD1 gene and is respon-
sible for childhood cystic disease with an incidence of
1:20,000 [3,4]. Although remarkable progress has been
made in understanding the function of the PKD genes, the
molecular and cellular mechanisms that lead to cyst for-
mation and enlargement in PKD kidneys are still not fully
understood.
Growing evidence suggests that abnormal extracellular
matrix (ECM) remodeling may represent a common
pathway for cyst formation and development in ADPKD
and ARPKD kidneys. Normal ECM remodeling is tightlyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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components. This tight regulation is essential for proper
morphogenesis during embryo development and for
maintaining tissue and organ structure homeostasis in
the adult [5,6]. During kidney development, ECM under-
goes active remodeling and the levels of both, collagens,
the main components of ECM, and MMPs, the main
enzymes that degrade ECM components, are dynamically
regulated. In particular, MMP2, MMP9, and MT1-MMP
have been shown to play an important role in regulating
local ECM remodeling during ureteric bud (UB) branch-
ing morphogenesis in kidney development [7,8].
Studies have shown that renal interstitial fibrosis, which
is caused by excessive accumulation and deposition of
collagens, is a characteristic feature of both ADPKD and
ARPKD. There is a strong correlation between the pro-
gression of interstitial fibrosis and the progression of cys-
tic disease [9,10]. In addition, overexpression of ECM
collagens has been observed in cultured PKD cells as well
as in PKD kidneys of human patients and animal models
[11-14]. Finally, gene expression profiling of cystic kidney
tissues from both human PKD patients and animal PKD
models has shown that a large portion of upregulated
genes encode for ECM proteins [15,16].
MMPs are key enzymes in ECM remodeling and their
overexpression is another characteristic feature of PKD
kidneys. Among the MMP family proteins, MMP2,
MMP9 and MT1-MMP are the main collagen degrad-
ation enzymes. It has been shown that the expressions of
these specific MMPs are increased in both PKD patients
and PKD animal models [17-19]. MT1-MMP has been
shown to play a unique role in modifying pericellular
collagen microenvironment and in regulating pro-MMP2
and pro-MMP9 activation. In addition to its collagen
degradation activity, MT1-MMP has also been shown
to be a potent mitogen for cell proliferation [20-22].
Increased cell proliferation and dynamic remodeling of
the microenvironment is a prerequisite for cyst enlarge-
ment, suggesting that MT1-MMP may be a major con-
tributor in cyst growth.
In the present study, we investigated the role of colla-
gen I and MT1-MMP in cyst formation and growth
using both in vitro 3D collagen I culture system and
in vivo PCK rat model of PKD. First, our studies reveal
that the initiation of cyst structures requires higher colla-
gen levels than that required for the formation of tubule
structures. Secondly, we find that MT1-MMP stimulates
cell proliferation and cyst enlargement. Finally, we show
that the treatment of PCK rats with doxycycline, an FDA
approved pan-MMPs inhibitor, significantly inhibited
cystic disease progression in polycystic kidneys. Taken
together, our results suggest that increased collagen
expression and MMP activity in PKD kidneys may play a
crucial role in renal cyst formation and enlargement.Methods
PCK rat model
3 to 4 weeks old male PCK rats were purchased from
Charles River (Wilmington, MA). The protocol for
animal studies has been approved by the Texas Tech
University Health Sciences Center Animal Care and Use
Committee. Rats had free access to tap water and stand-
ard rat chow. Male PCK rats were treated at 4 weeks
of age daily with either doxycycline (Sigma, St. Louis,
MO) at 30 mg/kg or vehicle (PBS) subcutaneously for
5 weeks.
Immunohistochemical staining
OCT-embedded kidney sections (5 μm) were used for
the immunohistochemical studies. For antigen ret-
rieval, the sections were first immersed in heated (95°C
to 100°C) 0.1 M citrate buffer, pH 6.0 for 10 min and
then allowed to cool to room temperature. The sections
were then incubated with the antibodies against collagen
I (Santa Cruz Biotechnology, Santa Cruz, CA), MMP2
(Millipore, Temecula, CA), MMP9 (Santa Cruz Biotech-
nology, Santa Cruz, CA) or MT1-MMP (Thermo Fisher
Scientific, Fremont, CA), respectively. After extensive
wash, the sections were incubated with horseradish
peroxidase (HRP)-conjugated polymer (DAKO EnVision
System, Carpinteria, CA) for 1 h, and the antigen sites
were visualized by incubating with the substrate - DAB.
Cell culture and transfections
MDCK cells were obtained from American Type Culture
Collection (Manassas, VA) and grown in Dulbecco’s
modified Eagle’s medium (DMEM)/Ham’s F12 (50:50)
medium supplemented with 10% fetal bovine serum
(FBS), 100 U/ml penicillin, and 100 U/ml streptomycin
(Mediatech, Manassas, VA). pMSCVGFP-MT1-MMP
expression vector is a gift from Dr. Zonghan Dai (Texas
Tech University HSC). Transfections of MDCK cells
with pMSCVGFP-MT1-MMP or pMSCVGFP control
vector were performed using Lipofectamine 2000 (Invi-
trogen, Carlsbad, CA), as described by manufacturer’s
procedure and the stably transfected clones were selected
by 5 μg/ml puromycin.
RNA isolation and RT-PCR
Total RNA was isolated using RNeasy Mini Kit (Qiagen,
Valencia, CA), as described in the manufacturer’s ins-
tructions. cDNA was synthesized using SuperScript III
First-strand Synthesis System (Invitrogen, Carlsbad, CA).
The RT-PCR was performed using the following primers:
MT1-MMP forward primer: 50-GGATACCCAATGCCC
ATTGGCCA-30, reverse primer: 50-CCATTGGGCATC
CAGAAGAGAGC-30; 28S RNA forward primer: 50-
TTGAAAATCCGGGGGAGAG-30, and reverse primer:
50-ACATTGTTCCACATGCCAG-30.
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Collagen I was obtained from BD Biosciences (San Jose,
CA). Collagen I concentration was determined using
Modified Lowry Protein Assay Kit (Thermo Scientific,
Pittsburgh, PA). The collagen I solutions with desired
concentration in DMEM containing 100 U/ml penicillin,
100 U/ml streptomycin, 10 mM Hepes (pH 7.2) and
1.2 mg/ml NaHCO3 were prepared on ice, and then
mixed with cells to make a cell-collagen suspension at a
density of 1 × 104 cells/ml. Aliquots of 0.4 ml of the
cell-collagen suspension were plated in a 24-well plate
and incubated for 30 min in a 37°C, 5% CO2 incubator
to allow collagen solidified. Complete culture medium
was then added on the top of collagen gel and cultured
for 9 days. To test the effect of MMPs on cyst growth,
the cultures were treated with doxycycline at a concen-
tration of 12.5ug/ml. To view the histological structure
of the cysts and tubules, the 3D cultures were embedded
in OCT at the end of experiment.
Western blotting analysis
Lysates from 2D cultures were prepared as described
previously [23]. To prepare lysates from 3D cultures, the
collagen gels were washed with PBS for 3 times and then
solubilized in RIPA buffer (1% Triton X-100, 1% deoxy-
cholate, 0.1% sodium dodecyl sulfate, 20 mM Tris–HCl,
pH 7.4, 0.16 M NaCl, 1 mM EGTA, 1 mM EDTA, and
15 mM sodium fluoride) containing protease inhibitor
cocktails (Sigma, St. Louis, MO). The mixtures were
kept on ice for 1 h with periodically vortexing and then,
centrifuged at 6000 rpm for 10 min at 4°C. The superna-
tants were collected as cell lysates. Because the 3D cul-
ture lysates prepared by this method may contain
collagen I, we first normalized these lysates for β-actin
contents by Western blotting analysis. The lysates con-
taining equal amount of β-actin were then separated onFigure 1 The levels of collagen I, MMP9, MMP2 and MT1-MMP are inc
of collagen I, MT1-MMP, MMP9 and MMP2 (brown) of 9 weeks old normal
B, D, F, and H) of PCK rats (Scale bars, 50 μm).a 10% SDS-PAGE gel and transferred to a PVDF mem-
brane (Bio-Rad, Hercules, CA). The membranes were
probed with the antibodies against GFP (Chemicon,
Temecula, CA) and PCNA (Santa Cruz Biotechnology),
respectively. To confirm equal loading, the membranes
were also probed with anti-β-actin antibody (Sigma,
St. Louis, MO). After incubated with HRP-conjugated
secondary antibodies, the immunoreactive proteins were
visualized by ECL detection system (Amersham Bios-
ciences Piscataway, NJ).
Cyst and tubule structure measurement and
statistical analysis
Images of cysts and tubules in 3D collagen gels were
captured and analyzed using an inverted microscope
(Nikon Eclipse TE 2000-U). This was performed by a
reviewer who was blinded to the identity of the treat-
ment modality. At least ten random areas were captured
for each treatment condition. The diameters of the cysts
were measured using NIS-Elements BR 2.30 software
and the mean and standard deviation were determined
using Excel software. Comparison of the means was per-
formed with the Student’s t-test. The P value < 0.05 was
considered statistically significant. Values are expressed
as mean ± STDEV.
Cyst volume density and kidney function
Hematoxylin-eosin-stained kidney sections cut longitu-
dinally through the midline were used to determine the
cyst volume density by point counting stereology [24].
The entire kidney section was counted to guard against
field selection variation. Serum creatinine levels were
measured using Creatinine Assay kit (BioVison, Mountain
View, CA). Blood urea nitrogen levels were measured
using MaxDiscovery™ Blood Urea Nitrogen Enzymatic
Assay Kit (B100 Scientific Corporation, Austin, TX).reased in PKD kidneys of PCK rats. Immunohistochemical staining
rat kidney (top panel, A, C, E and G) and PKD kidneys (bottom panel,
Figure 2 Effect of collagen I concentrations on the formation of cyst or tubule structures in 3D collagen I gel cultures. A. percentage of
cyst and tubule structures formed in 3D collagen gels with a collagen I concentration of 0.8, 1.0, 1.2, 1.5, 1.8 and 2.0 mg/ml, respectively. B. a
representative tubule and cyst section stained with DAPI to show the single cell layer of tubule and cyst structures (Scale bar, 50 μm). C. a
representative picture of cyst and tubule structures formed in 1.0, 1.2, and 1.8 mg/ml collagen I gels (Scale bars, 200 μm).
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Expression of Collagen I, MMP2, MMP9 and MT1-MMP
are increased in PKD kidneys of PCK rats
Immunohistochemical staining for collagen I, MMP2,
MMP9, and MT1-MMP was performed on PKD kidneys
harvested from 9 weeks old male PCK rats. Age-
matched male Sprague–Dawley rats were used for con-
trol. Figure 1 A and B shows that collagen I expression
is dramatically increased in PKD kidneys compared to
control. The high collagen I expression was observed in
pericystic areas as well as non-cystic, interstitial areas of
the PKD kidneys. Similarly, the expression of MT1-
MMP, MMP9 and MMP2 are all significantly increased
relative to the low levels expressed in control kidneys
(Figures 1C to 1H). Expression of these MMPs is
increased in the cyst epithelial cell areas as well as in the
interstitial of non-cystic tubule cells.Figure 3 MT1-MMP induces cell proliferation and cyst growth in 3D col
the MT1-MMP mRNA and protein expression in parental and MT1-MMP overe
expression in parental and MT1-MMP overexpressed MDCK cells that were cu
that were formed from parental MDCK cells or MT1-MMP overexpressing MD
collagen I gels. **p< 0.005 versus MDCK cells. *p < 0.005 versus MDCK MT1-MCollagen concentration determines the formation of cyst
or tubular structure in 3D culture
MDCK cells were cultured in 3D collagen gels at varying
collagen I concentrations to examine the effects of col-
lagen I concentrations on cyst formation and growth.
MDCK cells cultured in collagen I concentrations below
1.0 mg/ml do not form 3D structures; 3D structures be-
come apparent at concentrations exceeding 1.0 mg/ml.
MDCK cells form tubules in a 1.0 mg/ml 3D collagen I
gel. A mixture of cyst and tubule structures is formed
when cells are cultured in 1.2 mg/ml 3D collagen I gel. It
is important to note that the cyst to tubule ratio increases
as collagen I concentrations increase. Remarkably, only
cyst structures are formed when collagen I concentra-
tion reached to 1.8 mg/ml (collagen threshold for cyst for-
mation) (Figure 2A). These cyst and tubule structures
were confirmed by microscopy analysis of DAPI-stainedlagen I gel culture. A and B: RT-PCR (A) and western blot (B) analyses of
xpressed MDCK cells. C and D: Western blot analysis of the PCNA
ltured under 2D (C) or 3D (D) conditions. E. The diameters of the cysts
CK cells treated with or without Doxycycline for 9 days in 2.5 mg/ml
MP cells.
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picture of cyst and tubule structures formed at collagen I
concentrations of 1.0, 1.2, and 1.8 mg/ml.
MT1-MMP stimulates cell proliferation and cyst expansion
in 3D collagen gel cultures
To investigate the role of increased MMPs in PKD kidneys
in cyst enlargement, we transfected MDCK cells with a
MT1-MMP expression vector (MDCK-MT1-MMP cell).
The overexpression of MT1-MMP in MDCK cells was
confirmed at both mRNA (Figure 3A) and protein
(Figure 3B) levels.
Western blot analysis of proliferating cell nuclear anti-
gen (PCNA), a molecular marker for proliferating cells,
shows that the overexpression of MT1-MMP in MDCKFigure 4 Effects of doxycycline (Dox) on the development of PKD in P
vehicle-treated control (A) and PCK (B) rats as well as the doxycycline-treat
volume of the PKD kidneys. The cyst volume density (CVD) of the kidneys f
and from the doxycycline-treated control (+/+ Dox) and PCK (PKD Dox) rat
rats but decreased it in the PCK rats. *P < 0.001 versus +/+ vehicle, **p < 0.0
in PCK rats. The two-kidney/total body weight ratio (2 K/TBW) was examine
and were compared to that of doxycycline-treated control (+/+ Dox) and P
affect 2 K/TBW in +/+ rats but decreased it in the PCK rats. *p < 0.001 versu
did not significantly affect creatinine level. The creatinine levels were meas
and were compared to those in the doxycycline-treated control (+/+ Dox)
unaffected by doxycycline in +/+ rats. The PCK rats at 9 weeks of age have
the doxycycline treatment did not significantly affect BUN level.cells did not increase PCNA levels under a 2D culture
condition (Figure 3C). However, expression of PCNA
is significantly increased in 3D collagen I gel cultures
(Figure 3D). Moreover, the overexpression of MT1-
MMP in MDCK cells resulted in a shift of the collagen
concentration threshold for cyst formation from 1.8 mg/ml
to 2.5 mg/ml. To study the impact of increased MT1-
MMP expression on cyst enlargement, we compared the
growth of the cysts formed by parental MDCK cells to that
of the cysts formed by MDCK-MT1-MMP cells in 3D gels
with a collagen concentration of 2.5 mg/ml, at which both
cell lines form cysts predominantly. We found that the
overexpression of MT1-MMP significantly increased cyst
growth. Furthermore, the cyst growth was attenuated by
the addition of doxycycline (Figure 3E).CK rats. A to C. Representative kidney sections from the
ed PCK rat (C) (Scale bar, 1.5 cm). D. Doxycycline reduced the cyst
rom the vehicle-treated control (+/+ Veh) and PCK (PKD Veh) rats,
s was measured. The doxycycline treatment did not affect CVD in +/+
05 versus PKD vehicle. E. Doxycycline reduced the kidney enlargement
d in the vehicle-treated control (+/+ Veh) and PCK (PKD Veh) rats
CK (PKD Dox) rats, respectively. The doxycycline treatment did not
s +/+ vehicle, **p < 0.005 versus PKD vehicle. F. Doxycycline treatment
ured in the vehicle-treated control (+/+ Veh) and PCK (PKD Veh) rats
and PCK (PDK Dox) rats. *p < 0.001 versus +/+ vehicle. G. BUN was
a slight increase in BUN (*p < 0.005 versus +/+ vehicle); however,
Figure 5 Doxycycline inhibits MT1-MMP, MMP9 and MMP2
expression in polycystic kidneys of PCK rats. Immunohistochemical
staining (brown color) of vehicle-treated (A, C, E) and
doxycycline-treated kidneys (B, D, F) of PCK rats with antibodies
against MT1-MMP, MMP9, and MMP2, respectively (Scale bars:
50 μm).
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kidney enlargement
4 week-old male PCK rats were treated daily with
30 mg/kg doxycycline or vehicle for 5 weeks. The body
weight was 373 ± 7 g in vehicle-treated rats (n = 5) and
331 ± 11 g in doxycycline-treated rats (n = 5). Despite the
11% decrease in body mass, all of the rats seemed
healthy during the treatment. The cyst volume density
(CVD) in vehicle-treated PKD kidneys reached to 43%
and doxycycline reduced CVD to 30% (Figure 4D).
Figure 4A to C shows representative kidney sections
through midline of vehicle-treated normal rat kidney,
vehicle-treated PCK rat kidney, and doxycycline-treated
PCK rat kidney. The two-kidney/total body weight ratio
(2 K/TBW) was determined to correct for the lower
body mass caused by the doxycycline. The 2 K/TBW
ratio was 0.90 ± 0.04 (n = 8) in vehicle-treated +/+,
0.85 ± 0.04 in doxycycline-treated +/+ rats (n = 5),
1.42 ± 0.06 in vehicle-treated PCK rat kidney and
1.20 ± 0.04 in doxycycline-treated PCK rat (Figure 4E).
PCK rats had a 60% increase in kidney size compared
with +/+ control. Doxycycline reduced the kidney
enlargement by 56%.
The serum creatinine levels were 0.4 ± 0.01 and
0.4 ± 0.05 in vehicle- and doxycycline-treated +/+ control
rats, 0.68 ± 0.13 and 0.59 ± 0.14 in vehicle- and
doxycycline-treated PCK rats, respectively (Figure 4F).
BUN levels were 18 ± 0.4 and 17.3 ± 1.6 in vehicle- and
doxycycline-treated +/+ control rats, 21 ± 1.8 and
19 ± 2.6 in vehicle- and doxycycline-treated PCK rats,
respectively (Figure 4G). These results show that PCK
rats at 9 weeks of age had a slightly increased creatinine
and BUN levels compared to the age-matched control
animals (P < 0.001 and P < 0.005, respectively), but the
treatment with doxycycline did not significantly affect
creatinine and BUN levels.
Immunohistochemical staining shows that the expres-
sions of MT1-MMP, MMP9 and MMP2 were significantly
lower in doxycycline-treated PKD kidney compared
to vehicle-treated controls (Figure 5). The number of
PCNA-positive kidney tubule/cyst cells per 20 X power
field was 121± 15 in vehicle-treated PCK kidneys and
67± 9 in doxycycline-treated PCK rat (Figure 6). Repre-
sentative pictures are shown in Figure 6 B and C.
Discussion
Studies in human PKD patients and several PKD animal
models including Han: SPRD rats and pcy mice showed
that abnormal ECM remodeling, such as increased colla-
gen I level and MT1-MMP expression, are the charac-
teristic feature of PKD kidneys [15,16]. However, the
direct link of increased ECM collagen and MT1-MMP
on cyst formation and enlargement in PKD kidneys has
not been well described.In this study, we investigated the role of increased
collagen I and the collagenase MMPs on cystic kidney
disease progression using both in vivo PCK rats and
in vitro 3D collagen I cyst culture systems. PCK rats
are orthologous model of human ARPKD and have
been successfully used for testing several potential
therapeutic agents, therefore provide one of the best
animal models for studies of human PKD [25,26]. A
recent study has shown that there is an epithelial-
to-mesenchymal transition in cyst-lining cells of PCK
rats, suggesting that increased ECM production may
occur in the kidneys [27]. However, the expression of
ECM collagen and MMPs in PKD kidneys of PCK rats
has not been previously described. We show here that
the expression of collagen I, MMP2, MMP9 and MT1-
MMP in PKD kidneys of 9 week old PCK rats are all
significantly increased compared to the age-matched
normal control rats. This finding further supports the
proposition that abnormal ECM metabolism is a com-
mon feature of PKD. We found that increased collagen
and MMPs expression not only occurred in cyst-lining
epithelial cells, but also in the interstitial area in PKD
kidneys. These observations are in agreement with the
studies of pcy mice model by Okada et al, showing that
both cystic epithelial cells and interstitial fibroblasts
express higher levels of collagens compared to normal
controls [10].
Figure 6 Doxycycline decreases the number of PCNA positive tubule/cyst cells in PKD kidneys of PCK rats. A. The number of PCNA-
positive cells per 20X power field in vehicle- and doxycycline-treated PKD kidneys. *p < 0.005 versus PKD vehicle. B and C. The representative
pictures of PCNA nuclear staining (brown color) in vehicle- (B) and doxycycline-treated (C) PKD kidneys (Scale bars: 50 μm).
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for studies of epithelial cell tubule and cyst morphogen-
esis. However, past studies have primarily focused on the
role of signaling molecules, such as HGF and cAMP on
cyst and tubule structure development [28,29]. No stud-
ies have been conducted to directly examine the effect of
collagen concentrations and MMPs activities on cyst and
tubule morphogenesis of cultured cells. We found that
the formation of cyst structure requires a collagen con-
centration higher than that required for the formation
of tubular structure. Given that the increased collagen
expression has been detected in cystic epithelial cells
and adjacent fibroblasts, our results suggest that this
locally increased collagen production in PKD kidneys
may play a critical role in the initiation of cyst formation.
Finally, we assessed the effects of MMPs inhibition
by doxycycline on cystic disease progression in a PKD
animal model, PCK rat. Doxycycline, also known as
Periostat, is currently the only FDA approved MMPs
inhibitor. Doxycycline is used to treat several disorders
that are mediated by increased MMP activities such as
cancer and periodontal disease. It has been shown to be
potent in inhibiting the activities of a large number of
MMPs, including MMP2, MMP9, and MT1-MMP [30].
We show that doxycycline significantly inhibited MT1-
MMP, MMP9 and MMP2 expression and slowed cyst
disease progression in PCK rats. We also demonstrate
that doxycycline inhibits cyst growth in 3D collagen gel.
Increased cell proliferation is prerequisite to cyst expan-
sion and MT1-MMP has been shown to stimulate cell
proliferation in both in vivo and in vitro studies. In this
study, we showed that doxycycline inhibits MT1-MMP
expression and cell proliferation in PKD kidneys. The ef-
fect of MMPs inhibition on PKD progression has been
previously studied by Obermuller et al in Han:SPRD
PKD rats using batimastat, a synthetic inhibitor of
MMPs [31]. Their study show that the batimastat treat-
ment significantly decreased cyst number but not the
total cyst volume density in PKD kidneys. They pro-
posed that this is likely due to that the dosage ofbatimastat used in their study is too low to effectively
block the high amounts of MT1-MMP being expressed
in large cysts and therefore, to inhibit large cyst expan-
sion. They also indicate that the application of higher
doses of batimastat may increase side effect, in particu-
lar, renal dysfunction. In our study, we show that the
dosage of doxycycline used in our experiments not only
efficiently inhibits overall cyst volume density in PKD
kidney of PCK rats, but also avoid any apparent kidney
function damage and other side effects.
Conclusions
Our in vivo and in vitro data suggest that abnormal
increase in collagen and collagenase MMPs expression
may play an important role in cyst formation and
enlargement in PKD kidneys. The finding that doxycyc-
line markedly inhibits cyst growth in PCK rats suggests a
potential use of this drug in therapeutic intervention of
the cystic disease progression. As doxycycline has been
used successfully in treating human patients with several
disorders that are mediated by increased MMP activities,
we believe that it may provide a promising drug candi-
date for the treatment of human PKD patients.
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